Detail akcie BiomX Rg online

Business Summary: BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Biomx Inc revenues was not reported. Net loss increased from $3.2M to $22.9M. Higher net loss reflects Loss (income) from change in fair value decrease of 93% to $1.7M (income), Other expenses (income) decrease from $2.2M (income) to $52K (expense), Stock-based Compensation in SGA increase of 59% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $7.50 to -$15.51.